• Explore /
  • Poster
  • / First-in-human phase 1/2 trial evaluating TAC01-CLDN18.2 autologous T cells in CLDN18.2-positive solid tumors.

First-in-human phase 1/2 trial evaluating TAC01-CLDN18.2 autologous T cells in CLDN18.2-positive solid tumors.

Abstract Poster

Authors

Ecaterina Dumbrava

Ecaterina Elena Dumbrava

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX

Ecaterina Elena Dumbrava , Davendra Sohal , Daniel Olson , Samuel Saibil , Alejandro Urgelles , Maria Apostolopoulou , Amy Mueller , Kara M. Moss , Deyaa R Adib , Benjamin L. Schlechter , Syma Iqbal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers

Track

Esophageal and Gastric Cancer,Small Bowel Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05862324

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr TPS419)

DOI

10.1200/JCO.2024.42.3_suppl.TPS419

Abstract #

TPS419

Poster Bd #

N4

Abstract Disclosures

Similar Posters

First Author: Benjamin L. Schlechter

First Author: Hans Prenen

First Author: Maria Pia Morelli

First Author: Eileen Mary O'Reilly